RYZ101 Improves PFS in Phase 3 ACTION-1 Trial for GEP-NETs After Lutetium-177 Therapy / Actinium-225, ACTION-1 Trial, BMS, ...
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All ...
Visara, Inc., a Rockville, Maryland-based ophthalmology company and majority-owned subsidiary of NovaBridge Biosciences (Nasdaq: NBP), announced on ...
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize ...
Bristol Myers Squibb ( NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
Long-term use of anabolic-androgenic steroids (AAS) has serious consequences for the heart, according to a new study that has ...
Testosterone Cypionate is one of those medications a lot of TRT patients recognize by name without necessarily knowing much about it. You get the prescription. You learn the injection routine. You ...
Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy ...
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des ...
Below are the CEO and CFO prepared remarks from Johnson & Johnson's third-quarter 2026 earnings call. For the complete transcript, financial results, supplemental materials and additional information, ...
Pancake breakfast, 7-11 a.m., Esko Fire Station. $10 per person or $35 per family. Proceeds go to fire department equipment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results